{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:25:36Z","timestamp":1789079136409,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00535-025-02283-3","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:51:12Z","timestamp":1752771072000},"page":"1310-1321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line gemcitabine and nab-paclitaxel: a prospective study"],"prefix":"10.1007","volume":"60","author":[{"given":"Tomoya","family":"Emori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiya","family":"Nakahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kawaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Fukatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-9223","authenticated-orcid":false,"given":"Masayuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2283_CR1","doi-asserted-by":"publisher","first-page":"990s","DOI":"10.1093\/jn\/127.5.990S","volume":"127","author":"IH Rosenberg","year":"1997","unstructured":"Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990s\u20131s.","journal-title":"J Nutr"},{"key":"2283_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1532-5415.2007.01140.x","volume":"55","author":"MJ Delmonico","year":"2007","unstructured":"Delmonico MJ, Harris TB, Lee JS, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55:769\u201374.","journal-title":"J Am Geriatr Soc"},{"key":"2283_CR3","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/gerona\/61.10.1059","volume":"61","author":"BH Goodpaster","year":"2006","unstructured":"Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059\u201364.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2283_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ageing\/afz046","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:601.","journal-title":"Age Ageing"},{"key":"2283_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412\u201323.","journal-title":"Age Ageing"},{"key":"2283_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","volume":"15","author":"LK Chen","year":"2014","unstructured":"Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15:95\u2013101.","journal-title":"J Am Med Dir Assoc"},{"key":"2283_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300-307.e2.","journal-title":"J Am Med Dir Assoc"},{"key":"2283_CR8","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","volume":"15","author":"BH Tan","year":"2009","unstructured":"Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973\u20139.","journal-title":"Clin Cancer Res"},{"key":"2283_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.surg.2015.08.047","volume":"159","author":"S Okumura","year":"2016","unstructured":"Okumura S, Kaido T, Hamaguchi Y, et al. Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery. 2016;159:821\u201333.","journal-title":"Surgery"},{"key":"2283_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139749","volume":"10","author":"Y Choi","year":"2015","unstructured":"Choi Y, Oh DY, Kim TY, et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS ONE. 2015;10: e0139749.","journal-title":"PLoS ONE"},{"key":"2283_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10637-013-0053-6","volume":"32","author":"S Cousin","year":"2014","unstructured":"Cousin S, Hollebecque A, Koscielny S, et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest New Drugs. 2014;32:382\u20137.","journal-title":"Invest New Drugs"},{"key":"2283_CR12","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2283_CR13","unstructured":"Japan. TEBotCSi: Cancer Statistics in Japan 2019. Foundation for Promotion of Cancer Research; 2019 (Japanese)"},{"key":"2283_CR14","doi-asserted-by":"publisher","first-page":"102474","DOI":"10.18632\/oncotarget.19687","volume":"8","author":"G Zhang","year":"2017","unstructured":"Zhang G, Meng S, Li R, et al. Clinical significance of sarcopenia in the treatment of patients with primary hepatic malignancies, a systematic review and meta-analysis. Oncotarget. 2017;8:102474\u201385.","journal-title":"Oncotarget"},{"key":"2283_CR15","first-page":"2018","volume":"31","author":"PR Boshier","year":"2018","unstructured":"Boshier PR, Heneghan R, Markar SR, et al. Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31:2018.","journal-title":"Dis Esophagus"},{"key":"2283_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.pan.2021.03.002","volume":"21","author":"H Sato","year":"2021","unstructured":"Sato H, Goto T, Hayashi A, et al. Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: survival analysis using the Weibull exponential distribution model. Pancreatology. 2021;21:892\u2013902.","journal-title":"Pancreatology"},{"key":"2283_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pan.2021.12.013","volume":"22","author":"T Emori","year":"2022","unstructured":"Emori T, Itonaga M, Ashida R, et al. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy. Pancreatology. 2022;22:277\u201385.","journal-title":"Pancreatology"},{"key":"2283_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pan.2018.11.001","volume":"19","author":"Y Kurita","year":"2019","unstructured":"Kurita Y, Kobayashi N, Tokuhisa M, et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019;19:127\u201335.","journal-title":"Pancreatology"},{"key":"2283_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"2283_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.amjsurg.2007.12.057","volume":"197","author":"RA Smith","year":"2009","unstructured":"Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466\u201372.","journal-title":"Am J Surg"},{"key":"2283_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.amjsurg.2009.08.041","volume":"200","author":"I Bhatti","year":"2010","unstructured":"Bhatti I, Peacock O, Lloyd G, et al. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197\u2013203.","journal-title":"Am J Surg"},{"key":"2283_CR22","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2011.03.028","volume":"47","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47:2633\u201341.","journal-title":"Eur J Cancer"},{"key":"2283_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/bjc.2013.332","volume":"109","author":"M Stotz","year":"2013","unstructured":"Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416\u201321.","journal-title":"Br J Cancer"},{"key":"2283_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bjc.2013.701","volume":"110","author":"J Szkandera","year":"2014","unstructured":"Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014;110:183\u20138.","journal-title":"Br J Cancer"},{"key":"2283_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/ijms18040730","volume":"18","author":"M Piciucchi","year":"2017","unstructured":"Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil\/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int J Mol Sci. 2017;18:730.","journal-title":"Int J Mol Sci"},{"key":"2283_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.14701\/ahbps.2019.23.4.372","volume":"23","author":"M Ikeguchi","year":"2019","unstructured":"Ikeguchi M, Goto K, Watanabe J, et al. Clinical importance of preoperative and postoperative prognostic nutritional index in patients with pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 2019;23:372\u20136.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"2283_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1245\/s10434-016-5579-3","volume":"24","author":"Z Liu","year":"2017","unstructured":"Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP\/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 2017;24:561\u20138.","journal-title":"Ann Surg Oncol"},{"key":"2283_CR28","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920\u20136.","journal-title":"Clin Cancer Res"},{"key":"2283_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.21037\/jgo.2017.06.11","volume":"8","author":"GZ Murimwa","year":"2017","unstructured":"Murimwa GZ, Venkat PS, Jin W, et al. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017;8:808\u201315.","journal-title":"J Gastrointest Oncol"},{"key":"2283_CR30","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1016\/j.clnu.2021.06.026","volume":"40","author":"S Youn","year":"2021","unstructured":"Youn S, Chen A, Ha V, et al. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clin Nutr. 2021;40:4888\u201392.","journal-title":"Clin Nutr"},{"key":"2283_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jcsm.12267","volume":"9","author":"LE Daly","year":"2018","unstructured":"Daly LE, \u00c9adaoin NB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018;9:315\u201325.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2283_CR32","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1017\/S0007114520003463","volume":"125","author":"S Uemura","year":"2021","unstructured":"Uemura S, Iwashita T, Ichikawa H, et al. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. Br J Nutr. 2021;125:1140\u20137.","journal-title":"Br J Nutr"},{"key":"2283_CR33","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.clnu.2024.06.037","volume":"43","author":"PN Klassen","year":"2024","unstructured":"Klassen PN, Mazurak VC, Baracos V, et al. Dose optimization of pancreatic enzyme replacement therapy is essential to mitigate muscle loss in patients with advanced pancreatic cancer and exocrine pancreatic insufficiency. Clin Nutr. 2024;43:1900\u20136.","journal-title":"Clin Nutr"},{"key":"2283_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/00031348241272420","volume":"91","author":"M Matsumoto","year":"2024","unstructured":"Matsumoto M, Uwagawa T, Shirai Y, et al. Impact of preoperative osteosarcopenia and postoperative administration of pancrelipase on the prognosis of borderline resectable and unresectable locally advanced pancreatic cancer. Am Surg. 2024;91:65\u201375.","journal-title":"Am Surg"},{"key":"2283_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MPA.0000000000001753","volume":"50","author":"H Luo","year":"2021","unstructured":"Luo H, Galv\u00e3o DA, Newton RU, et al. Exercise medicine in the management of pancreatic cancer: a systematic review. Pancreas. 2021;50:280\u201392.","journal-title":"Pancreas"},{"key":"2283_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcsm.12201","volume":"8","author":"TS Solheim","year":"2017","unstructured":"Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8:778\u201388.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2283_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5946\/ce.2022.278","volume":"57","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Ohno E, Ishikawa T, et al. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Clin Endosc. 2024;57:112\u201321.","journal-title":"Clin Endosc"},{"key":"2283_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s10147-023-02455-2","volume":"29","author":"T Emori","year":"2024","unstructured":"Emori T, Itonaga M, Ashida R, et al. Impact of sarcopenia on recurrent biliary obstruction after EUS-guided biliary drainage in patients with malignant biliary obstruction. Int J Clin Oncol. 2024;29:286\u201396.","journal-title":"Int J Clin Oncol"},{"key":"2283_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/jhbp.970","volume":"28","author":"Y Koya","year":"2021","unstructured":"Koya Y, Shibata M, Oe S, et al. Impact of sarcopenia on recurrent biliary obstruction after insertion of self-expandable metallic stent in patients with malignant biliary obstruction. J Hepatobiliary Pancreat Sci. 2021;28:572\u201380.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2283_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0899-9007(02)00982-6","volume":"18","author":"FJ Padillo","year":"2002","unstructured":"Padillo FJ, Andicoberry B, Pera-Madrazo C, et al. Anorexia and malnutrition in patients with obstructive jaundice. Nutrition. 2002;18:987\u201390.","journal-title":"Nutrition"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02283-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02283-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:53:49Z","timestamp":1772207629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02283-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02283-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest regarding publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}